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Abstract
Background Previous studies have described the clinical
impact of infection in alcoholic hepatitis (AH) but none have
comprehensively explored the aetiopathogenesis of infec-
tion in this setting. We examined the causes, consequences
and treatment of infection in a cohort of patients with AH.
Methods We undertook a retrospective cohort study of
patients with AH admitted between 2009 and 2014 to seven
centres in Europe and the USA. Clinical and microbiological
data were extracted from medical records. Survival was anal-
ysed with Kaplan–Meier analysis and Cox proportional hazards
analysis to control the data for competing factors. Propensity
score matching was used to examine the efficacy of prophy-
lactic antibiotics administered in the absence of infection.
Results We identified 404 patients with AH. Of these, 199
(49%) showed clinical or culture evidence of infection. Gut
commensal bacteria, particularly Escherichia coli and Enter-
obacter species, were most commonly isolated in culture.
Fungal infection was rarely seen. Cultured organisms and
antibiotic resistance differed markedly between centres.
Infection was an independent risk factor for death (hazard ratio
for death at 90 days 2.33, 95% confidence interval 1.63–3.35,
p\0.001). Initiation of antibiotic therapy on admission in the
absence of infection did not reduce mortality or alter the inci-
dence of subsequent infections. Corticosteroid use increased
the incidence of infection but this did not impact on survival.
Conclusions In this large real-world cohort of patients with
AH, infection was common and was associated with
reduced short-term survival. Gram-negative, gut commen-
sal bacteria were the predominant infective organisms,
consistent with increased translocation of gut bacteria in
AH; however, the characteristics of infection differ
between centres. Infection should be actively sought and
treated, but we saw no benefits of prophylactic antibiotics.
Keywords Hepatitis, alcoholic  Infection  Liver diseases,
alcoholic
Introduction
Alcoholic liver disease (ALD) accounts for significant
morbidity and mortality globally, causing 14.5 million dis-
ability-adjusted life-years and nearly 500,000 deaths in 2010
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[1]. Alcoholic hepatitis (AH), typified by jaundice and
coagulopathy [2], is the most florid manifestation of ALD
[2]. Registry data from Denmark show an increasing inci-
dence of AH from 1999 to 2008, particularly in women and
older patients [3]. Severe AH is associated with a high
1-month mortality of approximately 15% [4, 5]. Despite
decades of research, no pharmacotherapies have been shown
to be unequivocally effective. [5, 6] Liver transplant is
controversial, but has shown benefit in highly selected cases
[7]. Most recently the largest randomised trial in AH to date
failed to show a categorical benefit for corticosteroids,
describing a non-statistically significant reduction in mor-
tality in patients treated with steroids at 1 month countered
by increased mortality at 6 months due to increased rates of
sepsis in the group receiving steroid therapy [5].
Infections occur frequently in AH. Bacterial infection
occurs in approximately half of patients admitted to
hospital with AH [8–13], with a recent study showing that
64% of patients had detectable signs of sepsis [13]. The
high incidence of infection is due to several factors:
defects in immune cell function in AH may predispose to
infection [14, 15], whereas changes in gut permeability
and dysbiosis result in translocation of gut-resident bac-
teria and endotoxin [16–18]. Moreover, secondary
mechanical effects on respiratory function such as
atelectasis due to abdominal ascites or hydrothorax pre-
dispose patients to pulmonary infection.
Infection in AH is associated with high mortality
[8, 19, 20]. This is particularly concerning given the
increased risk of infection with corticosteroid treatment,
although an important study by Louvet et al. [21], showed
corticosteroid use to be safe once infection had been con-
trolled. Many centres recommend the use of empirical
antibiotics [22]. This is not currently supported by evidence,
but trials are under way to investigate the efficacy of this
approach [23, 24]. Many trials have reported the overall
incidence of infection but data regarding the underlying
causes of infection are available only from smaller studies
[8]. This study examined a large, international cohort of
patients with AH to describe the incidence, distribution and
causes of infection in AH, the clinical consequences and the
effect of treatment with antibiotics and corticosteroids.
Methods
We studied a cohort of patients with AH admitted to our
institutions (University Hospitals Birmingham NHS
Foundation Trust, Bristol Royal Infirmary, Nottingham
University Hospitals NHS Trust and New Cross Hospital,
Royal Wolverhampton NHS Trust, all in the UK; Hospital
Universitario de Canarias, San Cristo´bal de La Laguna,
Spain; Mater Misericordiae University Hospital, Dublin,
Ireland; Mount Sinai Medical Center, New York, USA)
between 2012 and 2014. Cases were identified from
prospectively maintained databases in some centres
(Nottingham, Bristol, San Cristo´bal de La Laguna) or
identified retrospectively from hospital records with use
of International Statistical Classification of Diseases and
Related Health Problems tenth revision (ICD-10) codes
K70.1, K70.4 and K70.9. For retrospectively identified
cases, the diagnosis of AH was confirmed by careful
review of clinical and laboratory records. Patients were
included if there was a history of recent excessive alcohol
intake (guidelines in various countries are summarised in
Table S1), biochemistry findings consistent with AH
(bilirubin concentration greater than 150 mmol/L, with
aspartate aminotransferase and/or alanine aminotrans-
ferase concentration less than 300 IU/mL [2]) and no
evidence of other forms of liver disease in the history on
from blood tests for viral infection or metabolic disease.
Liver biopsy was not required for inclusion. Patients with
a history of AH in the preceding 6 months were excluded.
Data were collected regarding patient characteristics,
biochemistry, haematology, survival and antimicrobial
use. Missing data were not imputed. Patients were treated
according to local protocols without any study-specific
procedures. Corticosteroid or pentoxifylline use was at
the discretion of the treating clinicians. Where corticos-
teroids were prescribed, 40 mg prednisolone daily was
used, and response was gauged over 7 days of treatment
as per the Lille model [25]. As no study-specific proce-
dures were performed and only routinely collected data
were reviewed, we sought neither individual patient
consent nor specific research ethics approval. Applicable
institutional approvals are noted in the electronic sup-
plementary material.
The occurrence of infection at any point during hospital
admission was noted. Infection was defined as per previous
investigators [25, 26]:
1. Spontaneous bacterial peritonitis: ascitic fluid poly-
morphonuclear cell count greater than 250/lL with or
without positive fluid culture findings
2. Lower respiratory tract infection: new pulmonary
infiltrate on chest radiograph
3. Bacterial gastroenteritis: diarrhoea or dysentery with
positive stool culture findings
4. Clostridium difficile colitis: diarrhoea with positive
C. difficile toxin detection
5. Urinary tract infection: positive urine dipstick result
for leukocytes or nitrites, or urine white blood cell
count greater than 15 per high-power field with
positive urine culture findings in a symptomatic patient
6. Occult bacteraemia: positive blood culture findings
without a source of infection.
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Fever and leucocytosis are classically associated with
AH, and accordingly these factors were not considered
prima facie evidence of infection. Similarly bacteroascites
in the absence of an ascitic fluid polymorphonuclear cell
count greater than 250/lL was not considered to be de
facto evidence of infection.
Groups were compared with Student’s t test for nor-
mally distributed data or the Mann–Whitney test if data
were not normally distributed. Fisher’s exact test was used
for categorical data. Binary logistic regression to generate
odds ratios was used to examine factors predisposing to
infection. Survival was analysed with Kaplan–Meier
curves and Cox proportional hazards ratios calculated to
control the data for confounding factors. Data were cen-
sored after 12 months of follow-up. Propensity score
matching was used to investigate prophylactic antibiotic
use, with a match tolerance of 0.2 with a preference for
exact matches. Statistical analysis was performed with
IBM SPSS Statistics version 23 (IBM, Armonk, NY, USA).
Results
We identified 404 patients admitted to our institutions with
AH. The characteristics of the included patients are shown
in Table 1. Most of the patients were male and middle-
aged, consistent with recent participants in trials in AH
[5, 27]. Of these, 199 patients (49%) showed evidence of
infection. To consider the impact of variations in patients
and practice between our centres, we analysed differences
in the severity of disease (assessed with the discriminant
function), survival and prednisolone and antibiotic use
between our centres to inform subsequent analysis. The
severity of disease (one-way ANOVA p = 0.02),
prednisolone use (ANOVA p\ 0.01) and antibiotic use
(ANOVA p\ 0.01) differed significantly between centres.
Survival did not differ by centre (log-rank p = 0.207). The
incidence of infection did not differ significantly between
centres (chi–squared p = 0.10).
Patients with evidence of infection had higher creatinine
concentration (148 mg/dL vs 113 mg/dL, p = 0.004), higher
white blood cell count (14.5 9 109/L vs 12.5 9 109/L,
p = 0.028), lower albumin concentration (2.61 g/dL vs
2.77 g/dL, p = 0.016) and severer disease as assessed by the
discriminant function (121 vs 92, p = 0.009). In binary
regression analysis, higher creatinine concentration (odds
ratio 1.004, 95% confidence interval 1.001–1.007,p = 0.016)
and lower albumin concentration (odds ratio 0.953, 95%
confidence interval 0.916–0.991, p = 0.016) were the only
factors independently associated with infection (Table S2).
The presence of infection was associated with worse
survival by Kaplan–Meier analysis (log-rank p\ 0.001)
(Fig. 1). When other factors (age, bilirubin concentration,
creatinine concentration, prothrombin time, albumin con-
centration, white blood cell count and centre) were con-
trolled for by Cox proportional hazards analysis, infection
remained a significant risk factor for death at 28 days
(hazard ratio 1.92, 95% confidence interval 1.25–2.94,
p = 0.002), 90 days (hazard ratio 2.33, 95% confidence
interval 1.63–3.35, p\ 0.001) and 12 months (hazard ratio
2.01, 95% confidence interval 1.41–2.84, p\ 0.001) after
admission (Table S3, Fig. S1).
Of the 199 infections, 71 (36%) were evident at the time
of presentation to hospital and 128 (64%) developed during
admission. Infection was an early phenomenon, with 50%
of infections occurring within 24 h of admission and 73%
of infections occurring within 1 week of admission
(Fig. S2). No significant difference in survival was seen
Table 1 Characteristics of included patients
Entire cohort (n = 404) No evidence of infection (n = 205) Infection (n = 199) p (no infection
vs infection)
Average Variance Average Variance Average Variance
Age (years) 49.0 57 49.0 56 48.0 50 0.779
Prothrombin time (s) 28.5 11.7 29.6 10.0 29.5 13.2 0.101
Bilirubin (mmol/L) 330 182.1 320 176 341 187 0.241
Creatinine (mmol/L) 131 125 113 107 149 138 0.004
Sodium (mmol/L) 132.47 7.51 132 7.1 133 7.9 0.503
Urea (mmol/L) 24.28 35.32 20.7 29.9 28.0 39.8 0.031
Albumin (g/dL) 26.9 6.4 27.7 6.6 26.1 6.2 0.016
White blood cell count (9109/L) 13.53 9.42 12.51 8.9 14.6 9.9 0.028
Platelet count (9109/mL) 128.8 86.5 130.2 87.6 127 85.6 0.572
Discriminant function 106.3 113.2 91.8 75 121 140 0.009
Prednisolone use 156 (39%) 78 (39%) 78 (39%) 0.340
Data are shown as the number and percentage of patients for prednisolone use or as the mean and variance compared with the Mann–Whitney
test
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between patients with infection on admission and those
developing infection during admission (log-rank
p = 0.169).
Site and causes of infection
The commonest sites of infection were the chest in 80
patients (40%), the urinary tract in 69 patients (35%), the
peritoneum in 28 patients (14%) and blood in 21 patients
(11%) (Table 2). Five patients had microbiological evi-
dence of infection but outside the defined criteria: three
patients had bacteroascites—organisms grown on culture
of ascitic fluid, but without evidence of spontaneous bac-
terial peritonitis by the cell count criterion. In addition, one
patient had oesophageal candidiasis, one patient grew
Candida albicans from bile and one patient had PCR evi-
dence of C. difficile in stool without prior evidence of
infection. Short-term and medium-term mortality were
similar between all sites of infection (Fig. S3), but
12-month survival was worse in patients with lower res-
piratory tract infection and bloodstream infection com-
pared with those with urinary tract infection or spontaneous
bacterial peritonitis.
Organisms were grown from culture from 106 patients
with infections (53% of all infections). Cultured organ-
isms are listed in Table 2. Overall, there was a pre-
dominance of Gram-negative bacteria, accounting for
67% of isolated organisms, and Enterobacteriaceae in
particular. Escherichia coli was the most commonly
isolated single organism, found in 29 patients (27% of
all isolated organisms), and Enterobacter species were
grown in culture from 26 patients (25% of all infec-
tions). Gram-positive bacteria were less commonly seen
(19 cultures, 18% of all positive cultures). There was no
particular relationship between the type of isolated
organism and the site of infection. Candida was grown
in culture from three patients (3% of all positive culture
results), of whom two died during follow-up, both within
3 months of admission; however the overall the type of
organism grown in culture was not associated with sur-
vival (Fig. S4).
The site and cause of infection differed significantly
between geographical locations of the centres (Fig. 2).
Multiresistant organisms were seen in 24 cultures (22.6%
of all cultures). The most commonly seen was vancomycin-
resistant enterococcus (13 cultures), and also observed
were methicillin-resistant Staphylococcus aureus (cultured
from five patients), carbapenem-resistant enterococci (three
cultures) and organisms producing extended-spectrum b-
lactamases (four cultures). The presence of resistant
organisms did not appear to have an adverse effect on
survival (Supplementary Fig. 4).
Three blood cultures grew organisms that were consid-
ered potential contaminants: two coagulase-negative
Fig. 1 Survival of patients after
admission with alcoholic
hepatitis with or without
evidence of infection. Log-rank
p\ 0.001
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staphylococci and one Streptococcus milleri. All three
patients died within 12 months of admission, with a med-
ian survival of 4 months. Removal of these individuals
with potential contaminants from univariate Kaplan–Meier
survival analysis did not significantly change the results
(log-rank p\ 0.001). Ten cases of C. difficile infection
were observed, nine in patients who had previously been
treated for infection, and one in a patient without evidence
of prior infection. All patients had received antibiotics
before the diagnosis of C. difficile infection. The presence
of C. difficile did not appear to have an adverse effect on
survival: only two of this subgroup died during follow-up.
Antimicrobial therapy
Antimicrobial use was common: overall, 274 patients (68%)
were prescribed antibiotics, and 76 patients (19%) were pre-
scribed antifungal treatment. To examine the efficacy of
prophylactic antibiotics to reduce infection and improve sur-
vival, the subgroup of patients without infection at admission
was studied (Fig. S4), including 301 patients without evi-
dence of infection in the first 48 h of their admission. Pro-
phylactic antibiotic use was defined as antibiotic treatment
within 24 h of admission. No survival benefit was seen in
univariate Kaplan–Meier analysis. Indeed an apparent deficit
Table 2 Sites of infection and cultured organisms (excluding a single patient with positive Clostridium difficile PCR without prior infection)
Site of infection Number of
infections
Culture
negative
Culture positive
Number Species Number according
to species
Chest 80 56 24 Escherichia coli 1
Enterobacter species 9
Staphylococcus aureus 5
Corynebacterium 1
Neisseria polyscchaerae 1
Streptococcus pneumoniae 4
Lactobacillus minutus 1
Klebsiella 2
Urinary tract 69 18 51 Escherichia coli 24
Klebsiella species 9
Enterococcus species 10
Candida species 2
Mixed growth 2
Morganella morganii 1
Actinobacter baumannii 1
Stenotrophomonas maltophilia 1
Proteus mirabilis 1
peritoneum (i.e.,
ascitic
culture)
28 18 10 Escherichia coli 1
Klebsiella species 2
Eggerthella lenta 1
Methicillin-resistant Staphylococcus aureus 1
Pseudomonas aeruginosa 1
Enterobacter species 3
Candida albicans 1
Blood 21 0 21 Escherichia coli 3
Enterobacter species 4
Corynebacterium 1
Haemophilus influenzae 1
Streptococcus species 4
Klebsiella 1
Staphylococcus species 6
Actinobacter baumanii 1
Total 199 92 106
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in survival was seen with antibiotic use (log rank p = 0.04);
however, there were significant differences between groups
with regard to creatinine concentration and albumin concen-
tration (Table S4).
To address these differences and overcome some of the
difficulties of retrospective analysis, propensity score
matching was used to match equivalent patients who
received or did not receive prophylactic antibiotics. This
identified 50 patients given prophylactic antibtiotics mat-
ched on a 1:1 basis with controls. This process removed
any significant differences between groups (Table 3). No
reduction in overall infection rate was seen (40% vs 35% in
the prophylactic group and the non-prophylactic group
respectively, chi-squared p = 0.682) (Fig. 3a). Infections
occurred later in patients given prophylactic antibiotics
(median 10 days after admission vs 7 days in controls) but
this did not reach statistical significance (Mann–Whitney
test p = 0.310). Overall survival did not differ significantly
between the groups (Fig. 3b) (log-rank p = 0.051).
Corticosteroid use and infection
Overall, corticosteroids were prescribed in 156 patients
(39%) of the entire cohort. The same proportion of patients
received corticosteroids in non-infected and infected
groups (Table 1). After exclusion of patients with evidence
of infection at admission (total n = 332), we observed a
statistically significant increase in the overall incidence of
infection with corticosteroid treatment (70% in corticos-
teroid-treated patients vs 47% in non-treated patients,
Fisher’s exact test p = 0.027). For survival analysis, only
patients receiving corticosteroid therapy for more than
3 days were included (n = 147). Despite the increase in
the incidence of infections, a small but statistically sig-
nificant survival benefit of corticosteroids was observed
(hazard ratio 0.626, 95% confidence interval 0.405–0.969,
p = 0.036) at 28 days after admission.
Discussion
These detailed observations of 404 patients with AH from
centres in Europe and North America confirm that infection
is common in AH, seen in nearly half of patients, and is
associated with worse outcomes. Most infections seen in
AH are lower respiratory tract or urinary tract infections,
and are usually caused by Gram-negative gut commensal
bacteria. However, within the limits of this retrospective
Fig. 2 a Site and b cause of infection by geographical location of the centres
Table 3 Characteristics of patients with and without prophylactic antibiotic therapy after propensity score matching
Total No prophylactic antibiotics Prophylactic antibiotics p
Mean Variance Mean Variance Mean Variance
Age (years) 49.2 10.0 49.9 9.1 48.6 10.7 0.510
INR 2.2 1.5 2.3 1.5 2.2 1.4 0.791
Creatinine (mmol/L) 133.6 128.9 114.2 119.6 151.5 135.6 0.150
Sodium (mmol/L) 130.0 7.4 130.9 6.2 129.2 8.3 0.266
Urea (mmol/L) 17.5 25.1 20.1 24.0 15.2 26.0 0.333
Albumin (g/dl) 24.0 6.0 25.2 6.0 24.1 6.1 0.833
White blood cell count (9109/L) 11.9 7.2 11.3 6.9 12.6 7.5 0.377
Platelet count (9109/L) 122.4 80.7 117.9 85.3 126.5 77.0 0.597
INR international normalized ratio
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study, we observed that the use of antimicrobials early in
admission delayed but did not reduce the occurrence of
infections, without an effect on mortality.
This large, multinational study provides a greater level
of detail regarding infectious events in AH than has been
reported to date. We confirm that gut or urinary tract
commensal bacteria, particularly E. coli, are commonly
implicated in infections in AH. In contrast to a recent
report from Belgium, we did not find any cases of
aspergillosis [28], and we found only a few cases of can-
didias. Importantly, the underlying pathogens differ
between geographical locations and different units—for
example, the resistance patterns differed between centres in
this study, as did the incidence of C. difficile infection.
This emphasises the importance of local microbiological
expertise and protocols. Our retrospective data have limi-
tations. Screening for infection was not systematic and
depended on the practice of individual clinicians. Simi-
larly, there was no preagreed treatment protocol for treat-
ing infection when it was detected. The use of prophylactic
antibiotics (i.e. in the absence of hard evidence of infec-
tion) was common, and may reflect the severity of disease
that we were unable to control for despite multivariate
analysis.
This cohort describes a ‘real-life’ cohort, which will
differ from selected trial populations. Perhaps the most
important difference is that we defined AH on clinical
grounds rather than relying on biopsy. There is no con-
sensus regarding the necessity of biopsy [29], and recently
the NIAAA Alcoholic Hepatitis Consortia recommended a
biopsy for inclusion in studies only when doubt exists
regarding diagnosis [30]. It is notable that in the recent
STOPAH trial only a minority of patients underwent
biopsy [5]. Nevertheless, this may explain some differences
between our data and data from recent trials. In particular,
the overall incidence of infection in the STOPAH trial was
only 20% [5], much lower than the rates seen in our cohort.
Another large study, by Nguyen-Khac et al. [28], also
described a lower incidence of infection of approximately
30% over 6 months. In both trials, patients were excluded
from both trials for persistent infection at the baseline,
which may explain the differing observations. In common
with the STOPAH trial, we saw an increased risk of
infection with steroid use, but in contrast to the findings of
Louvet et al. [21], we did not observe a negative impact of
corticosteroids on survival in the presence of infection.
This latter point may be confounded by clinicians being
reluctant to use corticosteroids in patients with signs of
severe infection, a weakness of a retrospective approach.
Clinicians caring for individuals with AH should be
aware of the high risk of infection, and the increased
mortality associated with infection, particularly if it is
pulmonary or blood-borne. Systematic screening for
infection should be part of routine management of such
patients. The data presented here regarding likely causative
organisms can guide empirical therapy before cultures
results are available. Other measures such as management
of ascites, hydrothorax and nutritional therapy to improve
gut permeability are important. Although retrospective data
should be interpreted with caution, our data do not suggest
a benefit of antibiotic use in the absence of infection.
In summary, our data confirm the high burden of
infection in patients with AH. The early use of antibiotics
in high-risk patients to prevent subsequent infections or
improve survival is not supported. This will be clarified by
prospective clinical trials currently under way.
A B
Fig. 3 Efficacy of prophylactic antibiotic therapy: a incidence of infection with or without prophylactic antibiotics; b overall survival with or
without prophylactic antibiotics
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